对雇主赞助医疗保险男性勃起功能障碍治疗使用的商业数据库分析
该横断面索赔分析利用IBM MarketScan商业数据库,纳入2009-2017年至少一次ED诊断且当年连续参保的18-64岁男性,评估ED患病率及治疗利用情况。结果显示ED年患病率增加116%,但2017年仅23%诊断ED的男性接受了保险支付的治疗,PDE5I使用比例在18%-26%波动,阴茎假体植入率从0.23%降至0.11%。
要点
- 2009-2017年雇主保险男性ED年患病率增加116%,但治疗覆盖存在显著缺口。
- 2017年仅23%诊断ED的男性接受了保险支付的ED治疗。
- 阴茎假体植入率从2009年0.23%降至2017年0.11%,其他治疗及联合治疗率亦下降。
核心结论
- 雇主保险男性ED患病率显著增加,但约四分之三诊断ED的男性无治疗索赔,提示治疗可及性存在重大缺口。
研究设计与样本
- 横断面索赔分析,使用IBM MarketScan商业数据库,纳入2009-2017年18-64岁至少一次ED诊断且当年连续参保的男性。
主要发现
- 2009-2017年ED年患病率增加116%。
- 2017年仅23%诊断ED的男性接受保险支付的ED治疗。
- PDE5I使用比例从2012年18%至2015年26%波动。
- 阴茎假体植入率从2009年0.23%降至2017年0.11%。
- 其他ED治疗率从2009年0.94%降至2017年0.30%,联合治疗率从0.65%降至0.19%。
临床怎么用
- 泌尿外科医生应关注ED诊断后治疗可及性障碍,尤其保险覆盖不足的患者。
局限性
- 基于索赔数据,可能低估未寻求医疗或自费治疗的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the annual erectile dysfunction (ED) prevalence among men enrolled in an employer-sponsored health insurance (ESHI) plan and evaluate ED treatment profiles among those with an ED diagnosis. METHODS: A cross-sectional claims analysis was conducted using the IBM MarketScan Commercial Database, a nationally representative sample of US workers enrolled in ESHI plans. Patients aged 18-64 with at least one ED medical diagnosis claim and continuous enrollment in a given year between 2009 and 2017 were included. Among those with an ED diagnosis, utilization rates of the following ED treatments were determined: phosphodiesterase type 5 inhibitors (PDE5I), penile prosthesis implantation, other ED treatments (eg, vacuum pump, intraurethral suppositories), combination treatment, and no insurer-paid treatments. RESULTS: Between 2009 and 2017, the annual prevalence of men with ESHI suffering from ED increased by 116%. However, in 2017, only 23% of men with an ED diagnosis received an ED therapy paid for by their ESHI plans. The proportion of men taking PDE5Is ranged from 18% in 2012 to 26% in 2015. The proportion of men with ED undergoing penile prosthesis implantation has declined in recent years (0.23% in 2009 to 0.11% in 2017). Similarly, the rate of men who received other ED treatments or combination treatment has decreased from 2009 to 2017 (0.94%-0.30% and 0.65%-0.19%, respectively). CONCLUSION: ED prevalence among men insured by an ESHI plan has notably increased, yet approximately three-quarters of these men had no claims for ED treatments, indicating substantial access gaps to treatment.
引用
- Burnett AL, Rojanasarot S, Amorosi SL, et al. An Analysis of a Commercial Database on the Use of Erectile Dysfunction Treatments for Men With Employer-Sponsored Health Insurance. Urology. 2020. PMID: 33309705. doi:10.1016/j.urology.2020.11.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。